Mitochondrial Bioenergetics
How cells generate, allocate, and reserve energy for health and adaptation
Mitochondrial bioenergetics describes how cells transform nutrients and oxygen into usable energy, and how this energy is allocated across maintenance, signalling, repair, movement, and adaptation. ATP production is central, but it is not the whole story. Mitochondria also integrate information about fuel supply, oxygen, calcium, redox state, hormones, immune activity, and cellular stress.¹,² A healthy bioenergetic system therefore does more than maintain ATP at rest. It adjusts fuel use and respiratory output as demand changes while retaining sufficient reserve for exercise, infection, injury, psychological stress, and recovery. When this flexibility or reserve becomes constrained, the resulting symptoms may include fatigue, exercise intolerance, slower recovery, cognitive fatigue, and declining physical resilience. These features are clinically meaningful but non-specific, so bioenergetics should be used as a framework for understanding function and vulnerability rather than as a stand-alone diagnosis.³,⁴
What Are Mitochondrial Bioenergetics?
Every cell must continually solve an energy-allocation problem. Nutrients contain chemical energy, but cells cannot use that energy directly. Mitochondrial pathways extract electrons from carbohydrate-, fat-, ketone-, and amino-acid-derived substrates, use them to generate an electrochemical gradient across the inner mitochondrial membrane, and capture part of that stored energy as ATP.¹,⁵ ATP then powers contraction, ion transport, biosynthesis, signalling, and repair.¹
The familiar description of mitochondria as cellular powerhouses is useful but incomplete. Mitochondria operate as dynamic metabolic and signalling hubs. They sense the cellular environment and communicate their functional state through metabolites, reactive oxygen species, calcium fluxes, peptides, and changes in gene expression. In this broader view, bioenergetics sits at the interface between metabolism and cellular behaviour: it influences not only how much energy is available, but when, where, and for what purpose that energy is used.²,⁶
At a Glance
| Concept | Clinical meaning |
|---|---|
| Energy conversion | Fuel oxidation and electron transport generate a proton-motive force that supports ATP synthesis and other mitochondrial functions. |
| Metabolic flexibility | The ability to alter fuel use according to feeding, fasting, exercise, hormonal state, and tissue needs. |
| Coupling efficiency | The proportion of respiratory energy captured as ATP rather than dissipated through proton leak or heat. |
| Bioenergetic reserve | The capacity to increase respiratory and ATP-generating output when demand rises above baseline. |
| Energy allocation | The distribution of finite energetic resources across maintenance, movement, repair, immune defence, growth, and reproduction. |
| Core caution | Resting ATP, oxygen consumption, or membrane potential cannot be interpreted as universally healthy or unhealthy without tissue and physiological context. |
Why Mitochondrial Bioenergetics Matters
Every biological action carries an energetic cost, but different tissues face very different versions of the supply-and-demand problem. The heart must sustain continuous contraction. Neurons spend substantial energy maintaining ion gradients and synaptic transmission. Skeletal muscle can increase ATP turnover rapidly during exercise. The kidneys use ATP-intensive transport systems to reclaim filtered solutes, while pancreatic beta cells use mitochondrial metabolism to couple nutrient availability to insulin secretion. Immune cells remodel their metabolism as they activate, proliferate, and resolve inflammation.¹,⁷
These tissues do not simply need more energy. They need the right amount, in the right cellular compartment, at the right time. A patient may maintain sufficient ATP for resting function yet have limited capacity to respond to exertion, infection, poor sleep, or another physiological challenge. Conversely, increased respiration is not automatically beneficial if it reflects inefficiency, excessive proton leak, or compensatory demand. Bioenergetic health is therefore better understood as responsive, efficient, and adaptable energy conversion.³,⁸
How Cells Match Energy Supply, Demand, and Adaptation
From Fuel to an Electrochemical Gradient
Carbohydrates are broken down through glycolysis to pyruvate, which may enter mitochondria and be converted to acetyl-CoA. Fatty acids undergo beta-oxidation, while ketone bodies and selected amino acids enter through their own routes. These pathways converge on acetyl-CoA or tricarboxylic-acid-cycle intermediates. The TCA cycle transfers high-energy electrons to NADH and FADH₂, which deliver them to the electron transport chain.¹,⁵
As electrons move through respiratory-chain complexes, protons are pumped from the matrix into the intermembrane space. This generates the proton-motive force. ATP synthase then allows protons to flow back into the matrix and couples that movement to ATP formation. The same gradient also contributes to mitochondrial protein import, metabolite transport, calcium handling, and heat generation.¹,⁵
Metabolic Flexibility and Coupling
The dominant fuel used by a tissue changes with substrate availability, workload, and hormonal context. Healthy skeletal muscle increases carbohydrate oxidation as exercise intensity rises while retaining the capacity to oxidise fat at lower intensities and during fasting. The heart can use fatty acids, glucose, lactate, and ketones, but disease may alter this balance. This ability to shift between fuels is metabolic flexibility.⁷,⁹
Energy conversion is also shaped by coupling efficiency. Tightly coupled respiration captures a greater proportion of substrate energy as ATP, whereas proton leak dissipates part of the gradient as heat. Some leak is physiological and contributes to thermogenesis and redox control. Too much can reduce efficiency; too little may also alter redox behaviour. The interpretation depends on tissue and context rather than a simple more-is-better model.⁵,⁸
Bioenergetic Reserve: Capacity Beyond Rest
Cells generally retain capacity above their resting requirement. In experimental systems, spare respiratory capacity describes the difference between basal and maximal respiration. At a broader physiological level, bioenergetic reserve is the ability to raise energy production and redistribute resources when demand increases. This reserve can be recruited during exercise, immune activation, tissue repair, thermal stress, and other challenges.³,⁸
Reserve is clinically relevant because resting function can appear adequate while responsiveness is already compromised. The limitation may only become visible when a system is challenged. A person may function reasonably during routine activity yet experience disproportionate fatigue after exertion, a prolonged recovery from infection, or reduced tolerance of cumulative stressors. This does not establish mitochondrial disease, but it illustrates why functional capacity can be more informative than a static measure of energy at rest.³,⁴
The Energy Cost of Adaptation
Adaptation itself requires energy. Acute stress responses mobilise glucose and lipids, alter cardiovascular output, activate neuroendocrine pathways, and redirect resources toward immediate survival. Immune defence and tissue repair likewise require energy for signalling, protein synthesis, cell proliferation, and remodelling. When the challenge resolves, energy allocation can return toward routine maintenance and recovery.⁴,¹⁰
Picard and colleagues have extended the concept of allostatic load by placing energy metabolism and mitochondria within the stress-disease pathway. Their model proposes that repeated psychosocial and metabolic stress can create cumulative mitochondrial adaptations involving structure, function, signalling, and fuel regulation. Chronic elevations in glucose and lipids, glucocorticoid exposure, inflammation, and stress-related behaviours may reinforce this burden. The model is biologically plausible and influential, although it should not be interpreted as proof that psychological stress causes a single, uniform mitochondrial defect in every patient.⁴,¹⁰
Exercise illustrates the difference between an acute energetic challenge and chronic maladaptation. A training session temporarily increases ATP turnover, redox signalling, and repair demand. With sufficient recovery, repeated exercise stimulates mitochondrial biogenesis and improves oxidative capacity. By contrast, persistent demand without adequate recovery may narrow the margin between routine expenditure and available reserve. The clinical question is therefore not whether all stress is harmful, but whether the patient can adapt and recover from the total load being imposed.¹¹,¹²
When Energy Demand Exceeds Available Reserve
Bioenergetic disruption rarely means that a tissue has completely stopped producing ATP. More commonly, there is a loss of flexibility, efficiency, or reserve; altered substrate selection; impaired oxygen delivery; or increased energetic cost of maintaining homeostasis. These changes may be primary, as in inherited mitochondrial disease, but in routine practice they are more often investigated as contributors to or consequences of common multifactorial conditions.³,⁷
Cardiometabolic disease can disrupt fuel selection and increase mitochondrial oxidative stress. Cardiovascular disease may reduce oxygen and substrate delivery while increasing cardiac workload. Chronic inflammation reallocates nutrients toward immune defence and can alter mitochondrial metabolism. Ageing is associated with changes in mitochondrial quality control, biogenesis, dynamics, and respiratory capacity, although the magnitude and direction vary between tissues and individuals. Sleep disruption, physical inactivity, medication effects, nutrient deficiency, smoking, alcohol excess, and environmental exposures may add further strain.⁷,⁹,¹³
| Clinical context | Potential bioenergetic effect | Interpretive caution |
|---|---|---|
| Chronic inflammation or infection | Higher energetic demand from immune activation and repair; altered substrate use | Inflammation is heterogeneous and may be cause, consequence, or both. |
| Insulin resistance and type 2 diabetes | Reduced metabolic flexibility, altered cardiac and skeletal-muscle energetics, oxidative stress | Bioenergetic changes vary by tissue and disease stage. |
| Cardiovascular disease | Impaired oxygen delivery, increased workload, altered myocardial fuel use | Symptoms may chiefly reflect haemodynamic or structural disease. |
| Neurological disease | High neuronal energy demand combined with altered mitochondrial function or quality control | Associations do not establish mitochondrial dysfunction as the sole cause. |
| Ageing and frailty | Reduced reserve, lower physical capacity, and changes in mitochondrial turnover | Normal ageing must be distinguished from treatable disease and deconditioning. |
| Persistent psychosocial stress | Sustained neuroendocrine and behavioural demands may alter energy allocation | Life stress cannot be used to diagnose mitochondrial impairment. |
Practitioner Lens: Recognising Reduced Capacity Without Diagnosing ATP
Direct measurement of ATP production in living human tissues is not a routine clinical test. Research methods such as phosphorus magnetic resonance spectroscopy, high-resolution respirometry, extracellular flux analysis, muscle biopsy, and assessment of membrane potential can provide valuable information, but they are specialised, tissue-dependent, and not interchangeable. Even the myocardial phosphocreatine-to-ATP ratio is an index of cardiac energetic status, not a whole-body ATP test.¹⁴,¹⁵
In practice, clinicians are more likely to encounter functional patterns that could be compatible with constrained bioenergetic capacity: persistent fatigue, reduced exercise tolerance, post-exertional symptom worsening, slow recovery after illness or training, muscle fatigability, cognitive fatigue, and loss of physical resilience. None is specific to mitochondrial dysfunction. Anaemia, thyroid disease, sleep disorders, infection, mood disorders, medication effects, cardiopulmonary disease, nutritional deficiency, primary neurological or muscular disease, and other causes require appropriate assessment.³,¹⁶
The bioenergetic lens is most useful after this caution is made explicit. It encourages the clinician to ask whether energy demand, substrate availability, oxygen delivery, recovery, and functional reserve are reasonably matched. It does not replace differential diagnosis, and it should not be used to label non-specific symptoms as mitochondrial disease.
Supporting Mitochondrial Health in Clinical Practice
The practical aim is not to 'boost ATP' indiscriminately. It is to support the systems that preserve mitochondrial capacity, metabolic flexibility, oxygen delivery, and recovery. The most defensible approach begins with established health behaviours and management of the condition creating the energetic burden.
| Factor | Potential relevance | Clinical interpretation |
|---|---|---|
| Individualised physical activity | Stimulates mitochondrial biogenesis, oxidative capacity, vascular function, and functional reserve | Dose to current capacity; abrupt progression may worsen symptoms in some conditions. |
| Sleep and circadian regularity | Supports metabolic regulation, neuroendocrine recovery, and energy allocation | Investigate sleep apnoea, insomnia, shift work, and medication effects when relevant. |
| Cardiometabolic management | Improves substrate handling and may reduce chronic energetic strain | Prioritise evidence-based management of diabetes, hypertension, dyslipidaemia, and obesity. |
| Nutritional adequacy | Provides macronutrient substrate and micronutrient cofactors required for metabolism | Correct demonstrated deficiencies; avoid assuming that non-specific fatigue requires supplementation. |
| Stress and recovery strategies | May reduce sustained neuroendocrine demand and stress-related behaviours that affect metabolic health | Frame as part of total-load management, not as proof that symptoms are psychological. |
| Smoking, alcohol, and exposures | May influence oxygen delivery, redox balance, and mitochondrial function | Address within standard risk-reduction and occupational or environmental assessment. |
Exercise has the strongest human evidence as a physiological stimulus for mitochondrial adaptation, but the prescription must match the patient. Progressive aerobic and resistance training can improve oxidative capacity and functional performance in many populations. Patients with marked post-exertional symptom exacerbation, unstable cardiopulmonary disease, or suspected primary mitochondrial disease require a more cautious and condition-specific approach.¹¹,¹²
MitoQ Mitoquinol and Bioenergetic Function
MitoQ Mitoquinol is a mitochondria-targeted ubiquinone designed to accumulate within mitochondria through its lipophilic triphenylphosphonium moiety. Within the mitochondrial environment it can be reduced to the antioxidant ubiquinol form and recycled, providing a mechanistic rationale for limiting excessive mitochondrial oxidative stress while preserving redox signalling required for normal adaptation.¹⁷,¹⁸
The most directly relevant clinical evidence comes from a randomised, open-label, blinded-endpoint study in adults with type 2 diabetes without established cardiovascular disease. Participants received MitoQ Mitoquinol 40 mg/day or standard care for 16 weeks. Cardiac phosphorus magnetic resonance spectroscopy showed that the myocardial PCr/ATP ratio increased in the MitoQ group at rest from 1.58 to 1.78 and during dobutamine stress from 1.25 to 1.46. Peak early diastolic strain rate also increased, while left ventricular ejection fraction, perfusion, glycaemic control, and NT-proBNP did not significantly change.¹⁹ The findings are important because they demonstrate a human change in a tissue-specific energetic index alongside an early functional measure. However, the study was single-centre, open-label, and has been reported as conference material; it does not show that MitoQ universally raises ATP or prevents heart failure.¹⁹
A separate phase 2 double-blind, placebo-controlled study assessed MitoQ in dilated cardiomyopathy using cardiac and skeletal-muscle ³¹P-MRS. The publication provides further clinical investigation of myocardial energetics, but its population and disease stage differ from the type 2 diabetes study and the findings should not be combined as if they represent one clinical indication.²⁰
Other human studies support the broader biological rationale rather than directly measuring ATP. Six weeks of MitoQ improved brachial-artery flow-mediated dilation in healthy older adults and reduced markers consistent with lower mitochondrial oxidative stress. Exercise studies have reported reductions in exercise-induced oxidative damage, although effects on performance and training adaptation have varied by population and protocol. Together, the evidence supports MitoQ as a research-informed strategy for targeting mitochondrial oxidative stress, with the strongest bioenergetic signal currently limited to specific cardiac populations and surrogate or physiological outcomes.²¹,²²
What We Know, and What Remains Uncertain
There is broad agreement that mitochondrial ATP production, substrate oxidation, redox biology, calcium handling, and quality control are integrated rather than independent processes. Tissue function depends on the ability to adjust these processes as demand changes. Reduced respiratory reserve and altered energetics are observed across many diseases, but the direction, magnitude, and clinical meaning are tissue- and context-specific.¹,³,⁷
What remains uncertain is how best to translate cellular bioenergetic measurements into routine clinical decisions. Peripheral blood cells do not necessarily represent brain, heart, liver, or skeletal muscle. A normal resting marker may miss a deficit that emerges only under challenge, while an abnormal research readout may not predict symptoms or treatment response. The energetic model of allostatic load offers an important framework for linking life stress, metabolism, and physiology, but validated clinical thresholds and intervention algorithms are not yet available.⁴,¹⁰,¹⁴
For MitoQ Mitoquinol, the ATP/PCr-related cardiac data provide a clinically relevant proof of concept. Larger, fully published trials are needed to establish reproducibility, identify responsive populations, define the relationship between energetic indices and patient-centred outcomes, and determine whether changes persist beyond the intervention period.¹⁹,²⁰
Key Takeaways
Mitochondrial bioenergetics is the process by which cells transform and allocate energy, not simply a measure of ATP concentration.
Bioenergetic reserve describes the capacity to respond when demand rises and helps connect cellular physiology with exercise tolerance, recovery, and resilience.
Disease, inflammation, poor oxygen delivery, metabolic dysfunction, ageing, inactivity, sleep disruption, and persistent stress can alter energy demand, allocation, or reserve.
Fatigue and post-exertional symptoms may be compatible with reduced capacity but are non-specific and should not be used to diagnose mitochondrial dysfunction.
Clinical support should prioritise underlying-disease management, appropriately dosed activity, sleep, nutrition, metabolic health, and recovery.
MitoQ Mitoquinol has clinical evidence of improved myocardial PCr/ATP ratios and diastolic function in adults with type 2 diabetes, but this tissue-specific result should not be generalised to universal ATP enhancement.
References
1. Spinelli JB, Haigis MC. The multifaceted contributions of mitochondria to cellular metabolism. Nature Cell Biology. 2018;20:745-754. doi:10.1038/s41556-018-0124-1.
2. Picard M, Shirihai OS. Mitochondrial signal transduction. Cell Metabolism. 2022;34:1620-1653. doi:10.1016/j.cmet.2022.10.008.
3. Chacko BK, Kramer PA, Ravi S, et al. The Bioenergetic Health Index: a new concept in mitochondrial translational research. Clinical Science. 2014;127:367-373. doi:10.1042/CS20140101.
4. Bobba-Alves N, Juster RP, Picard M. The energetic cost of allostasis and allostatic load. Psychoneuroendocrinology. 2022;146:105951. doi:10.1016/j.psyneuen.2022.105951.
5. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148:1145-1159. doi:10.1016/j.cell.2012.02.035.
6. Picard M, McManus MJ, Csordas G, et al. Trans-mitochondrial coordination of cristae at regulated membrane junctions. Nature Communications. 2015;6:6259. doi:10.1038/ncomms7259.
7. Pinti MV, Fink GK, Hathaway QA, Durr AJ, Kunovac A, Hollander JM. Mitochondrial dysfunction in type 2 diabetes mellitus: an organ-based analysis. American Journal of Physiology-Endocrinology and Metabolism. 2019;316:E268-E285. doi:10.1152/ajpendo.00314.2018.
8. Nicholls DG. Spare respiratory capacity, oxidative stress and excitotoxicity. Biochemical Society Transactions. 2009;37:1385-1388. doi:10.1042/BST0371385.
9. Goodpaster BH, Sparks LM. Metabolic flexibility in health and disease. Cell Metabolism. 2017;25:1027-1036. doi:10.1016/j.cmet.2017.04.015.
10. Picard M, Juster RP, McEwen BS. Mitochondrial allostatic load puts the gluc back in glucocorticoids. Nature Reviews Endocrinology. 2014;10:303-310. doi:10.1038/nrendo.2014.22.
11. Egan B, Zierath JR. Exercise metabolism and the molecular regulation of skeletal muscle adaptation. Cell Metabolism. 2013;17:162-184. doi:10.1016/j.cmet.2012.12.012.
12. Granata C, Jamnick NA, Bishop DJ. Training-induced changes in mitochondrial content and respiratory function in human skeletal muscle. Sports Medicine. 2018;48:1809-1828. doi:10.1007/s40279-018-0936-y.
13. Sun N, Youle RJ, Finkel T. The mitochondrial basis of aging. Molecular Cell. 2016;61:654-666. doi:10.1016/j.molcel.2016.01.028.
14. Gnaiger E. Mitochondrial pathways and respiratory control. 5th ed. Bioenergetics Communications; 2020.
15. Levelt E, Rodgers CT, Clarke WT, et al. Cardiac energetics, oxygenation, and perfusion during increased workload in patients with type 2 diabetes mellitus. European Heart Journal. 2016;37:3461-3469. doi:10.1093/eurheartj/ehv442.
16. Parikh S, Goldstein A, Karaa A, et al. Patient care standards for primary mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in Medicine. 2017;19:1380. doi:10.1038/gim.2017.107.
17. Murphy MP, Smith RAJ. Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annual Review of Pharmacology and Toxicology. 2007;47:629-656. doi:10.1146/annurev.pharmtox.47.120505.105110.
18. Smith RAJ, Murphy MP. Animal and human studies with the mitochondria-targeted antioxidant MitoQ. Annals of the New York Academy of Sciences. 2010;1201:96-103. doi:10.1111/j.1749-6632.2010.05627.x.
19. Procter H, et al. Therapeutic potential of the mitochondrial antioxidant mitoquinone (MitoQ) in the treatment of diabetic cardiomyopathy. Heart. 2025;111(Suppl 3):A284. Conference abstract.
20. Halliday BP, Owen R, Ragavan A, et al. A double-blind, randomized placebo-controlled trial examining the effect of MitoQ on myocardial energetics in patients with dilated cardiomyopathy. European Heart Journal - Cardiovascular Imaging. 2026;27:74-77. doi:10.1093/ehjci/jeaf310.
21. Rossman MJ, Santos-Parker JR, Steward CAC, et al. Chronic supplementation with a mitochondrial antioxidant (MitoQ) improves vascular function in healthy older adults. Hypertension. 2018;71:1056-1063. doi:10.1161/HYPERTENSIONAHA.117.10787.
22. Shill DD, Southern WM, Willingham TB, et al. Mitochondria-specific antioxidant supplementation does not influence endurance exercise training-induced adaptations in circulating angiogenic cells, skeletal muscle oxidative capacity or maximal oxygen uptake. Journal of Physiology. 2016;594:7005-7014. doi:10.1113/JP272491.